AIGH Capital Management LLC Acquires New Position in Castle Biosciences, Inc. $CSTL

AIGH Capital Management LLC purchased a new stake in Castle Biosciences, Inc. (NASDAQ:CSTL) in the 3rd quarter, according to its most recent filing with the SEC. The fund purchased 707,287 shares of the company’s stock, valued at approximately $16,105,000. Castle Biosciences comprises about 4.5% of AIGH Capital Management LLC’s portfolio, making the stock its 9th largest position. AIGH Capital Management LLC owned 2.44% of Castle Biosciences at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Amundi boosted its stake in Castle Biosciences by 15,811.5% in the 1st quarter. Amundi now owns 4,137 shares of the company’s stock worth $79,000 after buying an additional 4,111 shares during the last quarter. AQR Capital Management LLC lifted its holdings in shares of Castle Biosciences by 548.9% during the 1st quarter. AQR Capital Management LLC now owns 137,022 shares of the company’s stock worth $2,743,000 after acquiring an additional 115,907 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Castle Biosciences by 4.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,441 shares of the company’s stock worth $309,000 after acquiring an additional 655 shares during the last quarter. Jones Financial Companies Lllp grew its holdings in Castle Biosciences by 10,592.0% in the first quarter. Jones Financial Companies Lllp now owns 2,673 shares of the company’s stock valued at $54,000 after purchasing an additional 2,648 shares during the period. Finally, Truist Financial Corp increased its position in Castle Biosciences by 7.7% during the second quarter. Truist Financial Corp now owns 24,023 shares of the company’s stock worth $491,000 after purchasing an additional 1,715 shares during the last quarter. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Castle Biosciences Trading Up 0.2%

NASDAQ:CSTL opened at $42.24 on Friday. The stock has a market cap of $1.23 billion, a price-to-earnings ratio of -93.87 and a beta of 1.06. Castle Biosciences, Inc. has a one year low of $14.59 and a one year high of $43.01. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.31 and a current ratio of 6.47. The business’s 50-day simple moving average is $39.20 and its 200 day simple moving average is $28.27.

Castle Biosciences (NASDAQ:CSTL) last issued its quarterly earnings data on Monday, November 3rd. The company reported ($0.02) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.32. Castle Biosciences had a positive return on equity of 1.73% and a negative net margin of 3.56%.The firm had revenue of $80.55 million during the quarter, compared to analyst estimates of $71.06 million. As a group, sell-side analysts predict that Castle Biosciences, Inc. will post 0.44 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on CSTL shares. Weiss Ratings reiterated a “sell (d)” rating on shares of Castle Biosciences in a report on Monday, December 29th. BTIG Research increased their target price on Castle Biosciences from $38.00 to $50.00 and gave the stock a “buy” rating in a research report on Friday, December 12th. Lake Street Capital boosted their price target on Castle Biosciences from $35.00 to $52.00 and gave the company a “buy” rating in a research report on Monday, January 12th. Guggenheim upped their price target on Castle Biosciences from $30.00 to $43.00 and gave the stock a “buy” rating in a research note on Monday, January 5th. Finally, Zacks Research lowered Castle Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Friday, January 2nd. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $46.00.

Insider Transactions at Castle Biosciences

In other Castle Biosciences news, COO Kristen M. Oelschlager sold 14,888 shares of the firm’s stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $39.31, for a total transaction of $585,247.28. Following the completion of the transaction, the chief operating officer directly owned 12,323 shares of the company’s stock, valued at $484,417.13. This trade represents a 54.71% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Derek J. Maetzold sold 4,017 shares of the company’s stock in a transaction dated Tuesday, January 20th. The shares were sold at an average price of $40.01, for a total transaction of $160,720.17. Following the completion of the sale, the insider owned 87,715 shares in the company, valued at approximately $3,509,477.15. This trade represents a 4.38% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 57,459 shares of company stock valued at $1,987,517. 6.50% of the stock is currently owned by corporate insiders.

About Castle Biosciences

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.